Major cost savings associated with biologic dose reduction in patients with inflammatory arthritis.
Antibodies, Monoclonal, Humanized
Receptors, Tumor Necrosis Factor
MetadataShow full item record
CitationMajor cost savings associated with biologic dose reduction in patients with inflammatory arthritis. 2015, 108 (1):19-21 Ir Med J
PublisherIrish Medical Journal
JournalIrish medical journal
AbstractThe purpose of this study was to explore whether patients with Inflammatory Arthritis (IA) (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS)) would remain in remission following a reduction in biologic dosing frequency and to calculate the cost savings associated with dose reduction. This prospective non-blinded non-randomised study commenced in 2010. Patients with Inflammatory Arthritis being treated with a biologic agent were screened for disease activity. A cohort of those in remission according to standardized disease activity indices (DAS28 < 2.6, BASDAI < 4) was offered a reduction in dosing frequency of two commonly used biologic therapies (etanercept 50 mg once per fortnight instead of weekly, adalimumab 40 mg once per month instead of fortnightly). Patients were assessed for disease activity at 3, 6, 12, 18 and 24 months following reduction in dosing frequency. Cost saving was calculated. 79 patients with inflammatory arthritis in remission were recruited. 57% had rheumatoid arthritis (n = 45), 13% psoriatic arthritis (n = 10) and 30% ankylosing spondylitis (n = 24). 57% (n = 45) were taking etanercept and 43% (n = 34) adalimumab. The percentage of patients in remission at 24 months was 56% (n = 44). This resulted in an actual saving to the state of approximately 600,000 euro over two years. This study demonstrates the reduction in biologic dosing frequency is feasible in Inflammatory Arthritis. There was a considerable cost saving at two years. The potential for major cost savings in biologic usage should be pursued further.
- Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
- Authors: Borrás-Blasco J, Gracia-Pérez A, Rosique-Robles JD, Casterá ME, Abad FJ
- Issue date: 2014 Feb
- Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
- Authors: Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM
- Issue date: 2012 Mar
- Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
- Authors: Carter CT, Changolkar AK, Scott McKenzie R
- Issue date: 2012
- Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
- Authors: Raffeiner B, Botsios C, Ometto F, Bernardi L, Stramare R, Todesco S, Sfriso P, Punzi L
- Issue date: 2015 Jan-Feb
- Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
- Authors: Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G
- Issue date: 2012 Dec